Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers

Hanft, J.R., Pollak, R.A., Barbul, A., Gils, C.van, Kwon, P.S., Gray, S.M., Lynch, C.J., Semba, C.P., Breen, T.J.·2008·Journal of Wound Care

Abstract

Objective: To assess the safety/tolerability and perform a preliminary efficacy evaluation of a multiple-dosing regimen of recombinant human vascular endothelial growth factor (VEGF 165 or rhVEGF; telbermin) applied topically to chronic diabetic neuropathic foot ulcers. Method: Subjects with type 1 or 2 diabetes mellitus were randomised to receive either topical applied telbermin (72µg/cm 2) (n=29) or placebo (n=26) treatment to the foot ulcer surface in conjunction with standard ulcer care. Subjects received treatment every 48 hours (maximum three doses per week) for up to six weeks. Weekly 35mm photography, quantitative planimetry and physical examinations documented the ulcer appearance, surface area and stage. Safety endpoints included incidence of clinically significant hypotension, adverse events and ulcer infection. Exploratory efficacy endpoints included percentage reduction in total ulcer surface area, incidence of complete ulcer healing and time to complete ulcer healing. Results: Incidence of adverse events was comparable in the two treatment groups. None of the adverse events were attributed to study drug, and no hypotension was observed as a result of telbermin treatment. Occurrence of infected study ulcers appeared to be balanced between the treatment groups. Positive trends suggestive of potential signals of biological activity were observed for incidence of complete ulcer healing (41.4% telbermin versus 26.9% placebo at day 43 [P=0.39]) and time to complete ulcer healing (25th percentile of 32.5 days telbermin versus 43.0 days placebo [log-rank P=0.13]). Conclusion: The topical application of telbermin 72µg/cm2 three times a week for up to six weeks appeared to be well tolerated. Further studies are required to characterise the safety/efficacy of telbermin more completely. Declaration of interest: Paul S. Kwon, Sarah M. Gray and Christopher J. Lynch are employed by Genentech, and own Genentech stock. Tim J. Breen was employed by Genentech before February 2006 and owns Genentech stock. Charles P. Semba was employed by Genentech before December 2007 and owns Genentech stock.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.12968/jowc.2008.17.1.27917

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 159

Metadata

Authors
Hanft, J. R., Pollak, R. A., Barbul, A., Gils, C. V., Kwon, P. S., Gray, S. M., Lynch, C. J., Semba, C. P., & Breen, T. J.
Venue
Journal of Wound Care
Published
2008-01
Volume
17
Issue
1
Pages
30-37
ISSN
  • 0969-0700 (ISSN-L)
  • 2052-2916
OpenAlex
W2077171235
Cited by
159
References
1
FWCI
3.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. https://app.cochat.ai/papers/10.12968/jowc.2008.17.1.27917
The paper
Hanft, J. R., Pollak, R. A., Barbul, A., Gils, C. V., Kwon, P. S., Gray, S. M., Lynch, C. J., Semba, C. P., & Breen, T. J. (2008). Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care. https://doi.org/10.12968/jowc.2008.17.1.27917

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.